MYOV News and Press, Myovant Sciences Ltd. From 02/25/22

Commercial-stage pharma company, Myovant Sciences (MYOV -0.7%) announced Friday that an expert panel of the European Medicines Agency (EMA) issued a positive opinion on Orgovyx for its approval in the treatment of adults with advanced hormone-sensitive prostate cancer. The decision by the EMA...

CHMP opinion recommending approval based on data from the global Phase 3 HERO study If approved, ORGOVYX® would be the first and only oral androgen deprivation therapy for ad...

Sumitomo Dainippon Pharma and Sumitovant Biopharma Initiate Phase 1 Study on New Drug Candidate for Carbapenem-Resistant Bacterial Infections Compound inhibits enzymes produced by bacteria that degrade carbapenem antibiotics PR Newswire LONDON and NEW YORK , ...

Image source: The Motley Fool. Myovant Sciences Ltd. (NYSE: MYOV) Q3 2021 Earnings Call Jan 26, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Myovant Sciences Ltd. (MYOV) Q3 2021 Earnings Call Transcript

CAMBRIDGE, Mass. and BASEL, Switzerland, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Enzyvant today announced the appointment of Johanna Rossell as Chief Commercial Officer. Johanna Rossell has an extensive background in the pharmaceutical and healthcare sector, leading multifunctional teams ac...

Third fiscal quarter 2021 total revenues of $54.4 million, including net product revenue of $29.3 million Net product revenue from U.S. sales of ORGOVYX ® of $24.4 million, reflecting 40% sequential volume growth compared to second fiscal quarter 2021, partially...

BASEL, Switzerland, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its third fiscal...

Estimated total revenue of $54.0-$55.0 million, including net product revenue of $28.8-$29.8 million Estimated ORGOVYX ® net product revenue of $24.2-$24.6 million, reflecting 40% sequential volume growth compared to fiscal second quarter 2021, partially offset by a l...

BASEL, Switzerland, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., will present at the 40th Annual J.P. Morgan H...

Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021 - Enzyvant, a wholly-owned subsidiary of Sumitovant, received FDA approval for RETHYMIC® (allogeneic processed thym...